Abstract We report the case of a 67-year-old man with metastatic papillary renal cell carcinoma (RCC) who developed bloody sputum after the administration of sunitinib. Chest computed tomography revealed diffuse ground-glass opacity lesions, and bloody bronchoalveolar lavage fluid was obtained by flexible bronchoscopy. The abnormal shadows promptly regressed after withdrawal of sunitinib. In four cycles of sunitinib treatment, he suffered from controllable diffuse alveolar hemorrhage. Finally, he died of respiratory failure 8 months after onset. This is the first case report of diffuse alveolar hemorrhage as an adverse effect of sunitinib in metastatic papillary RCC. Care should be taken with pulmonary hemorrhage in the use of anti-angiogenesis agents in not only squamous cell lung cancer, but also metastatic lung tumors.
Introduction
Renal cell carcinoma (RCC) is the most common kidney tumor, and the incidence has been increasing over the last several decades [1] . Although the most common histological type of RCC is clear cell carcinoma, papillary carcinoma makes up 7-14% of RCCs [2] . Treatment of advanced RCC with cytokines, such as interferon-a and interleukin-2, was the standard practice for a number of years [3] . Although the median survival period of patients with metastatic papillary RCC was reported to be only 5.5 months and no patients survived beyond 2 years [4] , a recent study indicated a 5-year survival rate for papillary RCC of 10% [5] . Thus, the prognosis has improved because novel molecular therapeutic agents have demonstrated significant clinical activity in advanced RCC and altered the standard therapy for this disease. Of these therapies, sunitinib, a new oral multitargeted receptor tyrosine kinase inhibitor (TKI), is promising for the treatment of RCC patients. In a phase III trial, progressionfree survival was longer, and the response rate was higher in patients with untreated metastatic RCC who received sunitinib than in those receiving interferon-a as conventional therapy [6] . The patients with papillary RCC treated with sunitinib had prolonged median progression-free survival of 11.9 months, although overall clinical responses remained low [7] . On the other hand, this agent shows a broad range of adverse effects 3-4 weeks after initiation of treatment, such as neutropenia, thrombocytopenia, asthenia, hypertension, and bullous skin toxicity. However, pulmonary bleeding as an adverse effect has seldom been reported.
Here, we report a case of metastatic papillary RCC complicated with diffuse alveolar hemorrhage because of sunitinib.
Case report
At the age of 67 years, the patient complained of a nonproductive cough in June 2008 and was subsequently hospitalized in July 2008.
He was a non-smoker. Although he had no family history of cancer, he had a history of tuberculous epididymitis at the age of 20, and was treated with oral therapy for diabetes mellitus and hypertension. The patients' blood cell counts were as follows (normal ranges are shown in parentheses): hemoglobin, 12.1 g/dl (13.5-17 . The results of renal function, coagulation, and collagen studies, such as myeloperoxidase-anti-neutrophil cytoplasmic antibody (MPO-ANCA), were normal. Whole-body computed tomography (CT) revealed a huge left renal tumor with multiple lung and liver nodules, and mediastinal lymph node swelling. In addition, positron emission tomography (PET) demonstrated accumulating spots in multiple bone tumor lesions. Pathological diagnosis using renal and pulmonary CT-guided needle biopsies showed type 1 papillary RCC with lung metastases. The clinical stage was determined to be T3bN0M1 (primary left renal tumor with lung, bone, liver, and mediastinal lymph node metastases) according to the TNM classification in August 2008.
On admission, his performance status was 1, but he suffered systemic metastases, and the tumor growth progressed rapidly. The tumor doubling time was 42 days. Therefore, he was spared cytoreductive nephrectomy for standard therapy and treated with sunitinib, a novel angiogenic inhibitor, as first-line systemic therapy in September 2008. Daily treatment with sunitinib showed efficacy with progression control in targeting primary and multiple lung and liver metastatic lesions. However, he suffered a small amount of bloody sputum (grade 1; Common Terminology Criteria for Adverse Events ver. 3.0) on day 5 and slight malaise (grade 1) on day 7. Administration of sunitinib was then interrupted because thrombocytopenia (grade 3) developed on day 18. On the same day, the chest CT scan revealed diffuse ground-glass opacity lesions around lung metastatic nodular shadows (Fig. 1a) . To investigate the abnormal shadows, flexible bronchoscopy was performed, and serous bloody bronchoalveolar lavage fluid was obtained from the superior lingular segment (Fig. 2) . After stopping sunitinib, he was treated with carbazochrome sodium sulfonate hydrate against diffuse alveolar hemorrhage, resulting in a marked reduction of the lesions determined by CT on day 40 (Fig. 1b) . Although he was treated with interferon-a after cessation of sunitinib, tumor growth indicated a rapidly progressive course. Then, he received four cycles of sunitinib until diffuse alveolar hemorrhage (grade 2) or thrombocytopenia (grade 3) was observed. In four cycles of sunitinib, controllable diffuse alveolar hemorrhage developed as well as first administration. Finally, the patient died of respiratory failure 8 months after the onset because of the progression of multiple lung and mediastinal lymph node metastases, and pleuritis carcinomatosa and lymphangitic carcinomatosis.
In the lung autopsy, diffuse peripheral alveolar hemorrhage was confirmed around the lung metastases (Fig. 3a) . To investigate the mechanism of diffuse alveolar hemorrhage by sunitinib, immunohistochemistry was performed for VEGF in the autopsy specimens of both lung tumors and primary renal tumors in addition to renal biopsy specimens. Although about 60% of tumor cells demonstrated weak cytoplasmic staining for VEGF in the renal biopsy, almost all tumor cells showed strong staining in both lung metastases and primary renal tumor in the autopsy (Fig. 3b) .
Discussion
Here we report the first case of diffuse alveolar hemorrhage as an adverse effect of sunitinib in metastatic papillary RCC. Sunitinib is an oral multitargeted TKI against VEGFR-1 and -2, platelet-derived growth factor (PDGF) [8] . Similar to other cancers, sunitinib has a major clinical impact for RCC. Recently, pulmonary bleeding has been reported to be an adverse effect with the development of antiangiogenic therapeutic approaches. Bevacizumab, a recombinant humanized monoclonal antibody that binds to VEGF, showed an adverse effect with fatal tumor-related bleeding, especially centrally located lung tumor or squamous cell histology, in patients enrolled in a randomized study for non-small cell lung carcinoma [9] . Sunitinib led to fatal pulmonary bleeding events in two patients with advanced squamous cell lung cancer in a phase II trial of previously treated advanced non-small cell lung cancer [10] . Therefore, ongoing trials for antiangiogenic agents tend to eliminate patients with squamous cell lung cancer. Furthermore, a retrospective study suggested that baseline tumor cavitation may be a potential risk factor for pulmonary hemorrhage in first-line advanced non-small cell lung cancer treatment with carboplatin and paclitaxel plus bevacizumab [11] .
The present case represents a timely warning regarding the clinical use of sunitinib for the following reasons: (1) the histological diagnosis was metastatic lung adenocarcinoma from RCC, but not squamous cell lung cancer, in which sunitinib-related diffuse alveolar bleeding has been reported; (2) lung metastatic tumors with hemorrhage were located in the peripheral side without cavitations; (3) the frequency of the use of sunitinib is anticipated to increase in the future. Therefore, care should be taken with regard to the adverse effects of sunitinib in cases of RCC lung metastases. However, the mechanism and clinical condition of sunitinib-associated pulmonary hemorrhage remain unclear.
VEGF is one of the principal proangiogenic factors in solid tumors and plays a pivotal role in vascular development, stimulating both angiogenesis and vasculogenesis [12, 13] . Papillary RCC tumors also show high levels of VEGF immunoreactivity [14] , and elevated VEGF mRNA levels in papillary RCC tumors were associated with short survival [15] . In addition, this growth factor is known as both a proangiogenic and survival factor for endothelial cells. Inhibition of VEGF results in inhibition of vascular development and significant alteration of epithelial development, suggesting that VEGF coordinates proper development of the normal lung epithelium and vasculature [16] . Therefore, it seems possible that inhibition of VEGF may decrease the regenerative capacity of the endothelial cells, resulting in endothelial dysfunction in the supporting layers of the blood vessels [17] .
In the present case, we speculated that the correlation with high-level production of VEGF from the tumor and the anti-VEGF effect of sunitinib in the lung metastatic microenvironment may have caused diffuse alveolar hemorrhage as adverse events because the tumor cells showed stronger expression of VEGF in both the primary site and the lung metastases at autopsy. On the other hand, Kontovinis et al. [18] reported that plasma VEGF-A levels increased after treatment with sunitinib in clear cell metastatic RCC. Therefore, we cannot rule out the possibility that anti-VEGF treatment itself might have induced the increased expression of VEGF in the autopsy specimens. In addition, pulmonary bleeding as an adverse effect of sunitinib has been reported only rarely in papillary RCC tumors. As we did not investigate other sunitinib-targeting molecules, such as PDGF, c-KIT, FLIT-3, and RET, further investigations regarding the mechanism of pulmonary hemorrhage are required.
In conclusion, we reported a case of metastatic papillary RCC with controllable diffuse alveolar hemorrhage as an adverse event associated with sunitinib. Care should be taken in cases of pulmonary hemorrhage with the use of anti-angiogenesis agents not only in squamous cell lung cancer, but also in metastatic lung tumors.
